CIK 0001438533
- Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- Operating
- EIN
- 262383102
- Phone
- +1 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,495,607
- in 10 filings, $79.5M under 10b5-1 plans
Net −$79,495,607. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 20 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-05-09 | Meckler Jeffrey A Director | Grant or award | +2,500 | 59,000 | ||
| 2018-05-09 | Meckler Jeffrey A Director | Grant or award · Employee Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2018-03-07 | ASELAGE STEVE Chief Executive Officer | Exercise or conversion | +278 | $6.00 | $2K | 221,383 |
| 2018-03-07 | ASELAGE STEVE Chief Executive Officer | Exercise or conversion · Common Stock Purchase Warrants | −278 | 0 | ||
| 2018-02-14 | ROTE WILLIAM E. Senior Vice President, R&D | Sale | −1,034 | $21.50 | $22K | 11,156 |
| 2018-02-08 | REED ELIZABETH E SVP, GC & Corporate Secretary | Grant or award | +1,769 | 10,827 | ||
| 2018-02-08 | ROTE WILLIAM E. Senior Vice President, R&D | Grant or award | +1,985 | 12,190 | ||
| 2018-02-08 | Clague Laura Chief Financial Officer | Grant or award | +2,033 | 2,033 | ||
| 2018-02-08 | McFarlane Neil F. Chief Operating Officer | Grant or award | +2,546 | 17,448 | ||
| 2018-02-08 | ASELAGE STEVE Chief Executive Officer | Grant or award | +3,549 | 221,105 | ||
| 2018-01-05 | REED ELIZABETH E SVP, GC & Corporate Secretary | Sale | −942 | $24.04 | $23K | 9,058 |
| 2017-12-26 | ASELAGE STEVE Chief Executive Officer | Gift | −23,000 | 217,556 | ||
| 2017-12-21 | ASELAGE STEVE Chief Executive Officer | Gift | −5,000 | 240,556 | ||
| 2017-08-16 | McFarlane Neil F. Chief Operating Officer | Sale | −1,378 | $22.50 | $31K | 13,622 |
| 2017-06-14 | ASELAGE STEVE Chief Executive Officer | Purchase | −5,000 | $17.85 | $89K | 245,556 |
| 2017-05-17 | KOZARICH JOHN W Director | Grant or award | +2,500 | 24,500 | ||
| 2017-05-17 | KOZARICH JOHN W Director | Grant or award · Employee Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2017-05-17 | LYONS GARY A Director | Grant or award | +2,500 | 26,500 | ||
| 2017-05-17 | LYONS GARY A Director | Grant or award · Employee Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2017-05-17 | Meckler Jeffrey A Director | Grant or award | +2,500 | 56,500 |
Page 52 of 59 · 1,174 trades